KALARIS THERAPEUTICS INC (KLRS) Fundamental Analysis & Valuation

NASDAQ:KLRS • US4829291065

Current stock price

6.3 USD
+0.23 (+3.79%)
Last:

This KLRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KLRS Profitability Analysis

1.1 Basic Checks

  • KLRS had negative earnings in the past year.
  • KLRS had a negative operating cash flow in the past year.
  • KLRS had negative earnings in each of the past 5 years.
  • KLRS had a negative operating cash flow in each of the past 5 years.
KLRS Yearly Net Income VS EBIT VS OCF VS FCFKLRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -35.68%, KLRS perfoms like the industry average, outperforming 59.57% of the companies in the same industry.
  • The Return On Equity of KLRS (-55.11%) is better than 60.15% of its industry peers.
Industry RankSector Rank
ROA -35.68%
ROE -55.11%
ROIC N/A
ROA(3y)-70.15%
ROA(5y)-57.85%
ROE(3y)-85.95%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
KLRS Yearly ROA, ROE, ROICKLRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KLRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLRS Yearly Profit, Operating, Gross MarginsKLRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. KLRS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KLRS has more shares outstanding
  • KLRS has less shares outstanding than it did 5 years ago.
  • KLRS has a worse debt/assets ratio than last year.
KLRS Yearly Shares OutstandingKLRS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
KLRS Yearly Total Debt VS Total AssetsKLRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • KLRS has an Altman-Z score of 0.00. This is a bad value and indicates that KLRS is not financially healthy and even has some risk of bankruptcy.
  • KLRS has a Altman-Z score of 0.00. This is comparable to the rest of the industry: KLRS outperforms 57.25% of its industry peers.
  • A Debt/Equity ratio of 0.41 indicates that KLRS is not too dependend on debt financing.
  • The Debt to Equity ratio of KLRS (0.41) is worse than 70.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 0
ROIC/WACCN/A
WACCN/A
KLRS Yearly LT Debt VS Equity VS FCFKLRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 12.23 indicates that KLRS has no problem at all paying its short term obligations.
  • KLRS's Current ratio of 12.23 is amongst the best of the industry. KLRS outperforms 85.69% of its industry peers.
  • KLRS has a Quick Ratio of 12.23. This indicates that KLRS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 12.23, KLRS belongs to the top of the industry, outperforming 85.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.23
Quick Ratio 12.23
KLRS Yearly Current Assets VS Current LiabilitesKLRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KLRS Growth Analysis

3.1 Past

  • KLRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.83%, which is quite impressive.
EPS 1Y (TTM)49.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.01% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.7%
EPS Next 2Y30.21%
EPS Next 3Y12.51%
EPS Next 5Y9.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KLRS Yearly Revenue VS EstimatesKLRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2027 2029 2030 2031 2032 2033 100M 200M 300M
KLRS Yearly EPS VS EstimatesKLRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. KLRS Valuation Analysis

4.1 Price/Earnings Ratio

  • KLRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLRS Price Earnings VS Forward Price EarningsKLRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLRS Per share dataKLRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KLRS's earnings are expected to grow with 12.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.21%
EPS Next 3Y12.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KLRS Dividend Analysis

5.1 Amount

  • No dividends for KLRS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KLRS Fundamentals: All Metrics, Ratios and Statistics

KALARIS THERAPEUTICS INC

NASDAQ:KLRS (4/10/2026, 8:00:02 PM)

6.3

+0.23 (+3.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)05-12
Inst Owners78.86%
Inst Owner Change0%
Ins Owners4.79%
Ins Owner Change-0.25%
Market Cap144.46M
Revenue(TTM)N/A
Net Income(TTM)-43.44M
Analysts85
Price Target19.38 (207.62%)
Short Float %4.47%
Short Ratio15.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)3.88%
Max EPS beat(2)5.93%
EPS beat(4)2
Avg EPS beat(4)-56%
Min EPS beat(4)-218.79%
Max EPS beat(4)5.93%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.15%
PT rev (3m)2.7%
EPS NQ rev (1m)15.69%
EPS NQ rev (3m)15.69%
EPS NY rev (1m)0%
EPS NY rev (3m)3.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-4.28
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0
BVpS3.44
TBVpS3.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.68%
ROE -55.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.15%
ROA(5y)-57.85%
ROE(3y)-85.95%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.23
Quick Ratio 12.23
Altman-Z 0
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.87%
EPS Next Y46.7%
EPS Next 2Y30.21%
EPS Next 3Y12.51%
EPS Next 5Y9.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.6%
OCF growth 3YN/A
OCF growth 5YN/A

KALARIS THERAPEUTICS INC / KLRS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KALARIS THERAPEUTICS INC (KLRS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KLRS.


What is the valuation status of KALARIS THERAPEUTICS INC (KLRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to KALARIS THERAPEUTICS INC (KLRS). This can be considered as Overvalued.


How profitable is KALARIS THERAPEUTICS INC (KLRS) stock?

KALARIS THERAPEUTICS INC (KLRS) has a profitability rating of 1 / 10.


What is the financial health of KALARIS THERAPEUTICS INC (KLRS) stock?

The financial health rating of KALARIS THERAPEUTICS INC (KLRS) is 4 / 10.